drugset / Trial / NCT05753592
A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Hepatic Impairment Compared With Matched Healthy Participants
Non-randomizedCrossoverOpen-labelTreatment
Summary
This was a Phase 1, open-label study to evaluate the PK, safety, and tolerability after administration of multiple doses of remibrutinib in participants with mild, moderate, or severe hepatic impairment (HI) compared to pooled matched healthy control participants with normal hepatic function.
Timeline
- Start
- 2022-10-31
- Primary completion
- 2023-12-14
- Completion
- 2023-12-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Remibrutinib | Small molecule | 25 mg | Oral |
Indications
No indication recorded.